Linked Life Data

19704066

Source:http://linkedlifedata.com/resource/pubmed/id/19704066

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
27
pubmed:dateCreated
2009-10-2
pubmed:abstractText
To compare the clinical activity of the pure antiestrogen fulvestrant at 500 mg/mo (double the approved dose) with the aromatase inhibitor anastrozole as first-line endocrine therapy for advanced hormone receptor-positive breast cancer in postmenopausal women.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1527-7755
pubmed:author
pubmed:issnType
Electronic
pubmed:day
20
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4530-5
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.
pubmed:affiliation
Division of Breast Surgery, University of Nottingham, Nottingham City Hospital, Hucknall Rd, Nottingham, NG5 1PB, United Kingdom. john.robertson@nottingham.ac.uk
pubmed:publicationType
Journal Article, Comparative Study, Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase II